Preclinical and early-phase clinical data are promising for the novel HIV capsid inhibitor GS-6207 and the NRTTI MK-8591. What roles could these long-acting injectables potentially serve in our treatment armamentarium?
Concerning data from an ongoing study evaluating ART exposure during pregnancy underscore the need for more research on drug safety in early pregnancy. How do the results of other ART pregnancy safety analyses reported this fall contribute to the existing body of knowledge?
What switch options can we offer to our patients with stable virologic suppression on older, more cumbersome ART regimens? Data from IAS, IDWeek, and Glasgow 2018 support novel booster-free options, including 2- and 3-drug combinations based on recently approved agents.